Prevention of chronic HBV infection induced hepatocellular carcinoma development by using antiplatelet drugs
Hepatocellular carcinoma (HCC) is a common malignancy affecting approximately one million people worldwide annually. It is one of the most common causes of cancer morbidity and mortality in Asia and Africa. The successful control of HCC in children after HBV vaccination further supports a role of chronic HBV infection in the development of HCC. Known risk factors for HCC include chronic viral infection, cirrhosis, extensive alcohol intake, non-alcoholic fatty liver disease, certain inherited metabolic conditions, environmental exposure, and transgenic oncogenes (1-4).